ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
ESSA Pharma Inc. (EPIX)
Last essa pharma inc. earnings: 2/13 05:48 pm
Check Earnings Report
US:NASDAQ Investor Relations:
essapharma.com/investors
Company Research
Source: PR Newswire
VANCOUVER and HOUSTON, April 30, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 with the FDA. EPI-7386 is a first-in-class N-terminal domain inhibitor of the androgen receptor. "This is an important milestone for ESSA and we look forward to commencing our clinical trial with EPI-7386 as a potential new therapy for the treatment of prostrate cancer," commented David R. Parkinson, MD, CEO of ESSA. "The timing of this IND acceptance keeps us on track with our initial clinical devel
Show less
Read more
Impact Snapshot
Event Time:
EPIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPIX alerts
High impacting ESSA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
EPIX
News
- ESSA Announces Completion of Arrangement with XenoTherapeutics [Yahoo! Finance]Yahoo! Finance
- ESSA Announces Completion of Arrangement with XenoTherapeuticsPR Newswire
- ESSA Securityholders Approve Acquisition by XenoTherapeutics [Yahoo! Finance]Yahoo! Finance
- ESSA Securityholders Approve Acquisition by XenoTherapeuticsPR Newswire
- ESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
EPIX
Earnings
- 5/8/25 - Beat
EPIX
Sec Filings
- 10/9/25 - Form 25-NSE
- 10/9/25 - Form 8-K
- 10/7/25 - Form SCHEDULE
- EPIX's page on the SEC website